Akne 2025 – neue Daten, neue Fakten, neuer Standard?

Acne vulgaris wird heute als eine Hautkrankheit mit multifaktorieller Entstehung betrachtet, wobei Entzündung eine wichtige Rolle spielt. Für die Therapie stehen zahlreiche topische und systemische Medikamente zur Verfügung. Welcher Wirkstoff für welchen Patienten individuell geeignet ist, hängt einerseits von der Krankheitsschwere, andererseits von der betroffenen Körperoberfläche (und somit der Wirkstoffexposition) sowie von Alter, Geschlecht und Kinderwunsch der Patienten ab.

Publication History

Article published online:
18 August 2025

• Literatur

• 1 Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol 2004; 22: 360-366
• 2 Del Rosso JQ, Bikowski JB, Baum E. et al. A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance. J Drugs Dermatol 2007; 6: 597-600
• 3 Pagliarello C, Di Pietro C, Tabolli S. A comprehensive health impact assessment and determinants of quality of life, health and psychological status in acne patients. G Ital Dermatol Venereol 2015; 150: 303-308
• 4 Gozali MV, Zhou B. Effective treatments of atrophic acne scars. J Clin Aesthet Dermatol 2015; 8: 33-40
• 5 Collier CN, Harper JC, Cafardi JA. et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol 2008; 58: 56-59
• 6 Zouboulis CC, Eady A, Philpott M. et al. What is the pathogenesis of acne?. Exp Dermatol 2005; 14: 143-152
• 7 Walton S, Wyatt EH, Cunliffe WJ. Genetic control of sebum excretion and acne – a twin study. Br J Dermatol 1988; 118: 393-396
• 8 Bekaert C, Song M, Delvigne A. Acne neonatorum and familial hyperandrogenism. Dermatology 1998; 196: 453-454
• 9 Jeremy AH, Holland DB, Roberts SG. et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003; 121: 20-27
• 10 Zouboulis CC, Böhm M. Neuroendocrine regulation of sebocytes – a pathogenetic link between stress and acne. Experimental Dermatology 2004; 13: 31-35
• 11 Alestas T, Ganceviciene R, Fimmel S. et al. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med (Berl) 2006; 84: 75-87
• 12 Dreno B, Gollnick HP, Kang S. et al. Understanding innate immunity and inflammation in acne: implications for management. J Eur Acad Dermatol Venereol 2015; 29 (Suppl. 04) 3-11
• 13 Schaller M, Loewenstein M, Borelli C. et al. Induction of a chemoattractive proinflammatory cytokine response after stimulation of keratinocytes with propionibacterium acnes and coproporphyrin III. Br J Dermatol 2005; 153: 66-71
• 14 Schäfer T, Nienhaus A, Vieluf D. et al. Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol 2001; 145: 100-104
• 15 Capitanio B, Sinagra JL, Ottaviani M. et al. Acne and smoking. Dermatoendocrinol 2009; 1: 129-135
• 16 Jansen T, Janßen OE, Plewig G. Acne tarda. Akne im Erwachsenenalter. Hautarzt 2013; 64: 241-251
• 17 Schmitt JV, Masuda PY, Miot HA. Acne in women: clinical patterns in different agegroups. An Bras Dermatol 2009; 84: 349-354
• 18 Orrell KA, Kelm RC, Murphrey M. et al. Frequency of acne in lactose-intolerant adults: a retrospective cross-sectional analysis within a large Midwestern US patient population. J Eur Acad Dermatol Venereol 2019; 33: e190-e191
• 19 Gollnick HP. From new findings in acne pathogenesis to new approaches in treatment. J Eur Acad Dermatol Venereol 2015; 29 (Suppl. 05) 1-7
• 20 Goulden V, Clark SM, Cunliffe WJ. Postadolescent acne: a review of clinical features. Br J Dermatol 1997; 136: 66-70
• 21 Poli F, Dreno B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol 2001; 15: 541-545
• 22 Ganceviciene R, Graziene V, Fimmel S. et al. Involvement of the corticotropin-releasing hormone system in the pathogenesis of acne vulgaris. Br J Dermatol 2009; 160: 345-352
• 23 Nast A, Bayerl C, Borelli C. et al. S2k-Leitlinie zur Therapie der Akne. J Dtsch Dermatol Ges 2010; 8: s1-s59
• 24 Nast A, Dréno B, Bettoli V. et al. European evidence-based (S3) guideline for the treatment of acne – update 2016 – short version. J Eur Acad Dermatol Venereol 2016; 30: 1261-1268
• 25 Loss MJ, Leung S, Chien A. et al. Adapalene 0.3% gel shows efficacy for the treatment of atrophic acne scars. Dermatol Ther (Heidelb) 2018; 8: 245-257
• 26 Dreno B, Bissonnette R, Gagne-Henley A. et al. Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6-month randomized, vehicle-controlled trial using intra-individual comparison. Am J Clin Dermatol 2018; 19: 275-286
• 27 Tan J, Thiboutot D, Popp G. et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol 2019; 80: 1691-1699
• 28 Blume-Peytavi U, Fowler J, Kemény L. et al. Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol 2020; 34: 166-173
• 29 Dreno B, Chavda R, Julia V. et al. Transcriptomics analysis Indicates trifarotene reverses acne-related gene expression changes. Front Med (Lausanne) 2021; 8: 745822
• 30 Schleicher S, Moore A, Rafal E. et al. Trifarotene reduces risk for atrophic acne scars: results from a phase 4 controlled study. Dermatol Ther (Heidelb) 2023; 13: 3085-3096
• 31 Kircik LH. Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of postinflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study. J Drugs Dermatol 2011; 10: 586-590
• 32 Kucera K, Zenzola N, Hudspeth A. et al. Benzoyl peroxide drug products form benzene. Environmental Health Perspectives. 132: 037702
• 33 Eichenfield L, Hebert A, Gold LS. et al. Openlabel, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris. J Am Acad Dermatol 2020; 83: 477-485
• 34 Mazzetti A, Moro L, Gerloni M. et al. Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, CB-03-01) topical cream, 1% in subjects with acne vulgaris: an open-label phase 2a study. J Drugs Dermatol 2019; 18: 563
• 35 McManus P, Iheanacho I. Donʼt use minocycline as first line oral antibiotic in acne. Bmj 2007; 334: 154
• 36 Sladden MJ, Harman KE. What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin?. Arch Dermatol 2007; 143: 1187-1188
• 37 Huang YC, Cheng YC. Isotretinoin treatment for acne and risk of depression: a systematic review and meta-analysis. J Am Acad Dermatol 2017; 76: 1068-1076.e1069
• 38 Gollnick H, Cunliffe W, Berson D. et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003; 49: S1-S37
• 39 Roberts EE, Nowsheen S, Davis MDP. et al. Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017. J Eur Acad Dermatol Venereol 2020; 34: 2106-2110
• 40 Santer M, Lawrence M, Renz S. et al. Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial. BMJ 2023; 381: e074349
• 41 Dreno B, Nguyen JM, Hainaut E. et al. Efficacy of spironolactone compared with doxycycline in moderate acne in adult females: results of the multicentre, controlled, randomized, double-blind prospective and parallel female acne spironolactone vs doxycycline efficacy (FASCE) study. Acta Derm Venereol 2024; 104: adv26002
• 42 Sadati MS, Yazdanpanah N, Shahriarirad R. et al. Efficacy of metformin vs. doxycycline in treating acne vulgaris: an assessor-blinded, add-on, randomized, controlled clinical trial. J Cosmet Dermatol 2023; 22: 2816-2823